본문으로 건너뛰기
← 뒤로

Debate: Improvements in Systemic Therapies for Liver Metastases Will Increase the Role of Locoregional Treatments.

1/5 보강
Hematology/oncology clinics of North America 📖 저널 OA 3.1% 2023: 0/1 OA 2024: 1/4 OA 2025: 0/1 OA 2026: 0/23 OA 2023~2026 2025 Vol.39(1) p. 207-220
Retraction 확인
출처

Kawaguchi Y, De Bellis M, Panettieri E, Duwe G, Vauthey JN

📝 환자 설명용 한 줄

The benefit of resection of liver metastases depends on primary diseases.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Kawaguchi Y, De Bellis M, et al. (2025). Debate: Improvements in Systemic Therapies for Liver Metastases Will Increase the Role of Locoregional Treatments.. Hematology/oncology clinics of North America, 39(1), 207-220. https://doi.org/10.1016/j.hoc.2024.08.009
MLA Kawaguchi Y, et al.. "Debate: Improvements in Systemic Therapies for Liver Metastases Will Increase the Role of Locoregional Treatments.." Hematology/oncology clinics of North America, vol. 39, no. 1, 2025, pp. 207-220.
PMID 39510674 ↗

Abstract

The benefit of resection of liver metastases depends on primary diseases. Neuroendocrine tumors are associated with favorable prognosis after resection of liver metastases. Gastric cancer has worse tumor biology, and resection of gastric liver metastases should be performed in selected patients. A multidisciplinary approach is well established for colorectal liver metastases (CLMs). Resection remains the only curative treatment of CLM. Chemotherapy and molecular-targeted therapy have improved survival in unresectable metastatic colorectal cancer. Understanding of the following two strategies, conversion therapy and two-stage hepatectomy, are important to make this patient group to be candidates for curative-intent surgery.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (5)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반